The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.
Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Hair loss discussion includes using hair fibers to improve appearance and boost confidence. Some users find it effective, while others mention drawbacks like moisture affecting the look.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
A naturally occurring sugar, 2-deoxy-D-ribose, in a hydrogel form, shows promise for hair regrowth similar to minoxidil in rats. The user plans to synthesize it for topical application, seeking input from others.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
A user is trying to make a topical finasteride solution by crushing tablets into ethanol and glycerin but struggles with spillage. Suggestions include letting the tablets dissolve in the solution or using a pill crusher for efficiency.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.
GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.
The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.
Hair fibers are discussed as a temporary solution for hair loss, with users noting they work well if applied correctly but can be messy and time-consuming. Some users also use finasteride for long-term treatment.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.